文献速递肿瘤 PET/CT核素与放射性配体治疗

趋化因子受体PET/CT为边缘区淋巴瘤提供相关分期及治疗管理改变

Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma.
PubMed 文献 · J Nucl Med · 2023-12-01

100例边缘区淋巴瘤患者行CXCR4靶向PET/CT,与指南兼容检查(CT、食管胃十二指肠镜、骨髓活检)比较。相对CT,27例(27.0%)Ann Arbor分期改变,其中23例从I/II期上调至III/IV期。CXCR4 PET信号增高与更短无进展生存期相关(707天 vs 中位未达到;HR 3.18;95%CI 1.37-7.35;P=0.01)。

要点

  • 相对CT,CXCR4 PET/CT使27/100例(27.0%)Ann Arbor分期改变。
  • 23例分期上调者中,治疗升级6/23(26.1%),降级17/23(73.9%)。
  • CXCR4 PET信号增高与更短PFS相关(707天 vs 中位未达到;HR 3.18;P=0.01)。

核心结论

  • 相对CT,CXCR4靶向PET/CT使27/100例患者Ann Arbor分期改变。
  • 趋化因子受体PET/CT可能改善当前诊断算法并影响相对单独CT的治疗管理,可能避免部分活检。

研究设计与样本

  • 本研究为100例边缘区淋巴瘤患者行CXCR4靶向PET/CT。
  • 比较分子影像与指南兼容检查(CT、食管胃十二指肠镜、骨髓来源活检)的分期结果和治疗决策。
  • 评估体内CXCR4 PET信号对无进展生存期(PFS)的预后价值(采用对数秩检验和Kaplan-Meier曲线)。
  • 确定在诊疗一体化背景下适合CXCR4靶向放射性配体治疗的患者数量。

主要发现

  • 相对CT,CXCR4靶向影像使27/100例患者(27.0%)Ann Arbor分期改变。
  • 其中,23例(85.2%)从AA I或AA II期临床相关上调至AA III或AA IV期,并伴随相应治疗管理改变(升级6/23[26.1%];降级17/23[73.9%])。
  • CXCR4 PET/CT相对食管胃十二指肠镜的诊断准确率为94.0%,相对骨髓来源活检为76.8%。
  • CXCR4 PET信号增高与更短PFS相关(707天 vs 中位PFS未达到;风险比3.18;95%CI 1.37-7.35;P=0.01)。
  • 18/100例患者(18.0%)适合CXCR4靶向放射性配体治疗。

关键数值与推荐

  • 相对CT,CXCR4靶向PET/CT使27/100例患者(27.0%)Ann Arbor分期改变。
  • 23/27例(85.2%)从AA I或AA II期上调至AA III或AA IV期。
  • CXCR4 PET/CT诊断准确率:相对食管胃十二指肠镜为94.0%,相对骨髓来源活检为76.8%。
  • CXCR4 PET信号增高与更短PFS相关:707天 vs 中位PFS未达到;HR 3.18;95%CI 1.37-7.35;P=0.01。
  • 18/100例患者(18.0%)适合CXCR4靶向放射性配体治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Because of gastral and extranodal manifestations, guideline-compatible diagnostic work-up of marginal zone lymphoma is challenging. We aimed to determine the diagnostic performance of C-X-C motif chemokine receptor 4 (CXCR4)-directed PET/CT compared with routine diagnostics, along with PET/CT-based retrospective changes in therapeutic management. The predictive potential of the PET signal was also investigated, and the number of patients eligible for CXCR4-directed radioligand therapy in a theranostic setting was determined. Methods: For this study, 100 marginal zone lymphoma patients underwent CXCR4-directed PET/CT. We compared staging results and treatment decisions from molecular imaging with respective results from guideline-compatible work-up (CT, esophagogastroduodenoscopy, and bone marrow-derived biopsy). Prognostic performance of the in vivo CXCR4 PET signal for progression-free survival (PFS) was evaluated (using log-rank test and Kaplan-Meier curves). Results: Relative to CT, CXCR4-directed imaging led to Ann Arbor (AA) staging changes for 27 of 100 patients (27.0%). Among those, clinically relevant upstaging from AA I or AA II to AA III or AA IV was observed for 23 patients (85.2%), along with respective changes in therapeutic management (escalation, 6/23 [26.1%]; deescalation, 17/23 [73.9%]). CXCR4 PET/CT yielded diagnostic accuracy of 94.0% relative to esophagogastroduodenoscopy and 76.8% relative to bone marrow-derived biopsy. An increased CXCR4 PET signal was linked to shorter PFS (707 d vs. median PFS not reached; hazard ratio, 3.18; 95% CI, 1.37-7.35; P = 0.01). CXCR4-directed radioligand therapy would have been feasible for 18 of 100 patients (18.0%). Conclusion: Relative to CT, CXCR4-directed PET/CT led to AA changes for 27 of 100 patients. Chemokine receptor PET/CT may improve current diagnostic algorithms and influence management relative to CT alone, potentially obviating some biopsies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Duell J, Buck AK, Hartrampf PE, et al. Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma. J Nucl Med. 2023. PMID: 37797975. doi:10.2967/jnumed.123.266074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。